This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 2000;284:293-295.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

New Orleans—Novel molecular strategies for targeting cancer cells came into focus here at the annual meeting of the American Society of Clinical Oncology, where some 22,000 cancer clinicians and researchers gathered to hear the latest findings emerging from the laboratory and clinical trials.

(Photo credit: ASCO/Todd Buchanan)

Researchers presented results from early studies of targeted therapies, experimental approaches that are intended to avoid the adverse effects of conventional chemotherapy or radiation treatment, which batter all rapidly dividing cells. Such approaches take aim at potential Achilles' heels of cancer cells, such as the greater numbers of receptors on the cancer cell surface (making the cells hypersensitive to growth factors and encouraging out-of-control growth) or a tumor's need for a nourishing network of blood vessels.

Some preliminary findings have been sufficiently encouraging that researchers have launched larger trials of novel agents. But some unexpected fatalities in one . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Acquired Resistance to the Antitumor Effect of Epidermal Growth Factor Receptor-blocking Antibodies in Vivo: A Role for Altered Tumor Angiogenesis
Viloria-Petit et al.
Cancer Res. 2001;61:5090-5101.
ABSTRACT | FULL TEXT